Literature DB >> 18954710

Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review.

David Pasquier1, Charles Ballereau.   

Abstract

PURPOSE: Given that postprostatectomy recurrence of prostate cancer occurs in 10-40% of patients, the best use of immediate postoperative radiotherapy (RT) in high-risk patients and salvage RT for biochemical recurrence remains a topic of debate. We assessed the levels of evidence (in terms of efficacy, prognostic factors, and toxicity) for the following treatment strategies: immediate postoperative RT alone, salvage RT alone, and the addition of androgen deprivation therapy to the two RT strategies. METHODS AND MATERIALS: A systematic literature search for controlled randomized trials, noncontrolled trials, and retrospective studies between 1990 and 2008 was performed on PubMed, CancerLit, and MEDLINE. Only relevant articles that had appeared in peer-reviewed journals were selected. We report on the levels of evidence (according to the National Cancer Institute guidelines) supporting the various treatment strategies.
RESULTS: Immediate postoperative RT improves biochemical and clinical progression-free survival (Level of evidence, 1.ii) but has no significant effect on metastasis-free survival or overall survival. A pathologic review is of particular importance for correctly analyzing the treatment strategies. Low-grade morbidity has been significantly greater in the postoperative groups, but no severe toxicity has been observed. The influence of immediate postoperative RT on postprostatectomy continence appears to be slight; therefore, immediate postoperative RT should be considered in patients with major risk factors for local relapse (Level of evidence, 1.ii). On the basis of extensive retrospective data, salvage RT is effective in biochemical relapse after prostatectomy; some patients with few adverse prognostic factors might also benefit from salvage RT (Level of evidence, 3.ii). The addition of androgen deprivation therapy to immediate postoperative or salvage RT has only been supported by weak, retrospective data (Level of evidence, 3.ii).
CONCLUSION: Prospective randomized trials are needed to compare immediate postoperative RT with salvage RT and to assess the value of androgen deprivation therapy in this setting.

Entities:  

Mesh:

Year:  2008        PMID: 18954710     DOI: 10.1016/j.ijrobp.2008.07.026

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain.

Authors:  A Gómez Caamaño; A Zapatero; J López Torrecilla; X Maldonado
Journal:  Clin Transl Oncol       Date:  2015-11-30       Impact factor: 3.405

2.  Incomplete prostatectomy for cancer.

Authors:  Mark Soloway
Journal:  Curr Urol Rep       Date:  2009-01       Impact factor: 3.092

3. 

Authors:  Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

4.  Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis.

Authors:  S P Elliott; T J Wilt; K M Kuntz
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-06-21       Impact factor: 5.554

5.  Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database.

Authors:  A Hervás; A Gómez-Caamaño; M Casaña; A Gómez-Iturriaga; J Pastor; J Jove; J L Mengual; C Gónzalez-San Segundo; J Muñoz
Journal:  Clin Transl Oncol       Date:  2017-06-30       Impact factor: 3.405

6.  Evaluating deviations in prostatectomy patients treated with IMRT.

Authors:  Ana Cravo Sá; Ana Peres; Mónica Pereira; Carina Marques Coelho; Fátima Monsanto; Ana Macedo; Adrian Lamas
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-29

7.  Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.

Authors:  J Paul Monk; Susan Halabi; Joel Picus; Arif Hussain; George Philips; Ellen Kaplan; Tim Ahles; Lin Gu; Nicholas Vogelzang; William K Kelly; Eric J Small
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

8.  Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.

Authors:  Tim J Kruser; David F Jarrard; Andrew K Graf; Sean P Hedican; David R Paolone; John D Wegenke; Glenn Liu; Heather M Geye; Mark A Ritter
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

9.  [Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy].

Authors:  T Martin; F Wenz; D Böhmer; F Sedlmayer; W Hinkelbein; T O Henkel; K Miller; T Wiegel
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

10.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens.

Authors:  Ralph A Bundschuh; Christina M Wendl; Gregor Weirich; Mathias Eiber; Michael Souvatzoglou; Uwe Treiber; Hubert Kübler; Tobias Maurer; Jürgen E Gschwend; Hans Geinitz; Anca L Grosu; Sibylle I Ziegler; Bernd Joachim Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-07       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.